Alluvi Retatrutide 40mg Pen – High-Dose Triple Agonist for Maximum Fat-Burning

Alluvi Retatrutide 40mg Pen is a high-dose peptide formulation activating GLP-1, GIP, and Glucagon receptors simultaneously. Designed for intensive metabolic research, it offers powerful tools for studying weight loss, appetite suppression, and improved glycemic control.

Each pen contains 40mg of Retatrutide in a convenient, pre-dosed injectable format. Backed by Alluvi's strict quality controls and third-party testing, it’s ideal for researchers exploring advanced fat-burning strategies and insulin pathways.

Key Features:

• High-potency triple receptor agonist
• 40mg per pen for extended use or high-dosage protocols
• Supports glucose regulation, fat oxidation, and reduced appetite
• GMP-grade research quality by Alluvi Healthcare

How to Use Alluvi Retatrutide:
Form: Prefilled injectable pen

Dosage: Start at 0.25–0.5 mg weekly, titrate to 3.0–5.0 mg per protocol

Cycle Length: 12–16 weeks, tapering optional

Administration: Weekly subcutaneous injection

How It Works:

• GLP-1 Agonism: Suppresses appetite and enhances insulin sensitivity
• GIP Pathway: Boosts pancreatic response and lipid metabolism
• Glucagon Activation: Increases thermogenesis and energy expenditure

Recommended Stacks:
Combine with:

VLS Semaglutide or Synedica Tirzepatide for advanced metabolic outcomes

Please be aware that Alluvi healthcare have upgraded the packaging for this product. You may receive either version but both are exactly the same Retatrutide pen.